Shifting towards emerging trial designs can be a huge hurdle for study teams. From decentralized trials to clinical research as a care option (CRAACO), creating a holistic strategy means leveraging the right mix of technology, operational expertise and data.
In this webinar, panelists will discuss emerging trends in healthcare that drive CRAACO adoption, lessons learned by sponsors about how to build and implement decentralized clinical trials (DCT), as well as how to develop a robust development strategy with CRAACO studies. Participants will gain an understanding of the critical building blocks to allow them to build DCT and CRAACO strategies.
Register for this webinar to learn firsthand about the different emerging trial designs to set your team up for success.
Kent Thoelke, Chief Scientific Officer, PRA
As PRA’s Chief Scientific Officer, Mr. Thoelke provides corporate oversight and strategy for Scientific & Medical Affairs, Pharmacovigilance & Patient Safety, Therapeutic Centers of Excellence, Real World Data, Patient Access & Experience, Digital Health & Virtual Trials, and their integration into operational delivery. Mr. Thoelke is an industry pioneer in the application of mobile first strategies, which integrate clinical trials and provide access directly to patients in both virtual and hybrid-virtual models. He emphasizes leveraging real world data, social insights, and patient connectivity to advance global drug development.Message Presenter
Isaac R. Rodriguez-Chavez, Ph.D., M.H.S., M.S., Senior Vice President for Scientific and Clinical Affairs, PRA Health Sciences
Dr. Rodriguez-Chavez joined PRA Health Sciences as a Senior Vice President for Scientific and Clinical Affairs. He is a biomedical leader with expertise in Virology, Microbiology, Immunology, Vaccinology, and Viral Oncology. His expertise spans basic, translational, preclinical and clinical research (phase I – IV global trials). He also has expertise in digital health technologies, clinical research development and operations, regulatory affairs, approval or licensure of medical products, and quality control and quality assurance.Message Presenter
Who Should Attend?
Senior professionals (Directors, VPs, CEOs) from US and EU pharmaceutical and biotech companies involved in:
- Clinical Operations
- Clinical Research
- Clinical Monitoring
- Clinical Trials
- Patient Experience
- Patient Engagement
- Patient Recruitment
- Study Management
- Trial Design Innovation
- Virtual Trials / Remote Trials /Decentralized Trials
What You Will Learn
In this webinar participants will learn about:
- Emerging trends in healthcare that will drive CRAACO adoption by providers and patients
- Lessons learned to build and implement a first (or upcoming) DCT
- How to future-proof development strategies with CRAACO and real-world studies
- The critical building blocks to help participants build their DCT and CRAACO strategy
PRA Health Sciences
PRA Health Sciences delivers innovative drug development solutions that improve patients’ lives. Our people are passionate about clinical research, working tirelessly to provide quality results. We offer exceptional experience across all phases and therapeutic areas and a broad spectrum of solutions, ranging from full-service clinical development to a pioneering embedded model.
With 16,000+ employees covering 90+ countries, we bolster an impressive global presence with keen local insights. Our project teams harness their understanding of local regulations, standards of care and cultural customs to effectively align our approaches with each study’s unique goals.
At PRA, we love what do because we are making a difference in the lives of patients and their family members worldwide. Over the years, we have contributed to the development of numerous drugs now available to countless patients. From our scientific and medical experts to therapeutically aligned project managers and monitors, we provide the commitment and expertise needed for today’s complex studies.